cascADe: Courses On-demand Expert AD Educators

Jerry Barakos, MD
California Pacific Medical Center
Sutter Health Hospitals/Bioclinica
San Francisco, California

Dr. Barakos completed his radiology residency and neuroradiology fellowship at the University of California, San Francisco. For the past 25 years, he has been in clinical practice as Director of Neuroimaging at the California Sutter Hospital System in San Francisco. Additionally, for the past 15 years, Dr. Barakos has worked with Bioclinica, serving as the lead neuroradiologist, having participated in more than 30 phase 3 neurodegenerative disease drug trials. Since starting with the bapineuzumab trials, Dr. Barakos has an interest in ARIA and has worked closely with many luminaries in the AD field, such as Reisa Sperling and Steve Salloway, to help define this condition.

Tammie Benzinger, MD, PhD
Washington University in St. Louis
School of Medicine
St. Louis, Missouri

Dr. Tammie Benzinger's research focuses on the integration of MR and PET for neuroimaging, with an emphasis on preclinical (asymptomatic) Alzheimer's disease (AD). She is the Director of the Knight Alzheimer Research Imaging (KARI) Program at Washington University, which focuses on advanced neuroimaging techniques for assessing healthy aging and early AD. She has extensive experience with amyloid and tau PET tracers in the setting of healthy aging, AD, and autosomal dominant AD. As Imaging Core Leader for the Dominantly Inherited Alzheimer Network (DIAN) and its Clinical Trials Unit (DIAN-TU), she directs MRI and PET protocol construction and validation, site set-up, imaging QC, processing, and primary imaging analysis. Through the work of DIAN, she played a key role in establishing the first proof of a 20-year phase of amyloid positivity, prior to symptom onset, in a 2012 *The New England Journal of Medicine* publication. She further elaborated this in 2013 with a detailed regional analysis of MRI and PET findings in the DIAN cohort. Her research has also made significant contributions to image processing, including the problem of partial volume correction in PET and use of image-derived arterial input functions.

Goldie Smith Byrd, PhD
Maya Angelou Center for Health Equity
Wake Forest School of Medicine
Winston-Salem, North Carolina

Professor Byrd is currently professor and director of the Maya Angelou Center for Health Equity at Wake Forest School of Medicine, Winston-Salem, North Carolina, where she leads the Integrating Special Populations Core (ISP) and the largest African

American faith-based network in the state, in addition to co-leading the Outreach, Recruitment, and Education (ORE) Core for the Alzheimer Disease Research Center. Her research centers on the genetics of Alzheimer disease in African Americans, with a strong interest in closing the research participation gap in minority communities. This work has inspired her to improve literacy, family support, resource access, and caregiver training for this underserved group; to that end, she has a great interest in developing community leaders who advance racial and health equity.

Professor Byrd founded COAACH (Center for Outreach in Alzheimer's, Aging and Community Health) at North Carolina Agricultural and Technical State University (N.C. A&T) in Greensboro and remains professor and acting director. In her time as COAACH's executive director, the Center received more than $5 million in grants and corporate gifts from the National Institutes of Health and the National Science Foundation. Through successful outreach programs and her transparency in research studies, Professor Byrd's work has helped to establish trusting relationships between COAACH and African American communities.

Following a degree in biology from N.C. A&T, Professor Byrd obtained her doctoral degree in microbial genetics and physiology from Meharry Medical College, Nashville, Tennessee. She held the position of assistant professor of biology at Tennessee State University, in Nashville, and at North Carolina Central University, in Durham, North Carolina. In 2005, she joined Duke University's Department of Medicine as adjunct assistant professor of genetics. In the same year, she returned to N.C. A&T as professor and chair of biology. In 2011, she was appointed professor and dean for the College of Arts and Sciences.

Monica Crane, MD
Genesis Neuroscience Clinic
University of Tennessee Medical Center, Dept. of Medicine
Knoxville, Tennessee

Dr. Monica Crane is a fellowship-trained geriatric medicine physician who has been recognized as an expert in dementia care in the Southeast. Her career focus has been the clinical care, treatment and support for patients and families affected by Alzheimer's disease and the related dementias.

Dr. Crane completed her undergraduate degree at Yale University and her medical school training at Jefferson Medical College in Philadelphia. She completed her residency and fellowship at the University of Pennsylvania, Philadelphia. During her fellowship, she was honored as a new investigator by the NIMH for her study of the behavioral symptoms due to Alzheimer's disease. She has received numerous clinical and research awards in the areas of Alzheimer's disease, geriatric depression, frontotemporal dementia and end-of-life care.

Dr. Crane is the founder and medical director of Genesis Neuroscience Clinic, a multidisciplinary memory disorders clinic. The clinic provides community care for mild cognitive impairment and the neurodegenerative dementias. This unique model of care incorporates support from local non-profits, including Alzheimer's Tennessee, Knox County Senior Services, the Purple Cities Alliance, and the University of Tennessee-Knoxville and the Graduate School of Medicine-UTMCK. The clinic serves as an opportunity to mentor students and health care professionals in geriatric medicine and dementia care. The current mentorship program has sponsored more than 40 mentees since 2017.

The Genesis Neuroscience Clinic team has seen more than 4000 patients to date. Since the clinic opened in 2017, Dr. Crane has been the PI for 6 major clinical trials in Alzheimer's disease and related dementias.

In 2020, Dr. Crane started the process to convert the practice into a charitable clinic under the Tennessee Memory Disorders Foundation. The Foundation mission is to provide support for comprehensive community care for those with memory disorders and to mentor students and professionals to become future leaders in dementia care. The focus of the mentorship program is to provide leadership opportunities for minority and socioeconomically disadvantaged students.

Prior to 2017, Dr. Crane was Director of Clinical Research as well as the Associate Director of Cole Neuroscience Clinic. Dr. Crane is also an Assistant Professor of Medicine at UT-Knoxville, Graduate School of Medicine.

Dr. Crane has served on the Board of Directors at Alzheimer's Tennessee since 2007, at the Knoxville Museum of Art since 2015, and the Tennessee Memory Disorders Foundation since 2020. She has been a leader in the Outreach Workgroup for the Society of Nuclear Medicine and Molecular Imaging. She has also been recognized as a leader by the East Tennessee community as an inductee of Leadership Knoxville and the Executive Women's Association. Under her leadership, the Knoxville community started a frontotemporal dementia conference, as well as an educational series with the goal of raising Alzheimer's and related dementia awareness.

Jeffrey Cummings, MD, ScD
University of Nevada, Las Vegas
Las Vegas, Nevada

Dr. Cummings is the Joy Chambers-Grundy Professor of Brain Science, Vice Chair for Research, and Director of the Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV). Dr. Cummings is a world-renowned Alzheimer's researcher and leader of clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer's disease through the Henderson Award of the American Geriatrics Society (2006), the Ronald and Nancy

Reagan Research Award of the national Alzheimer's Association (2008), and the Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017). In 2010, he was honored by the American Association for Geriatric Psychiatry with its Distinguished Scientist Award. In 2018, he was honored with the Leadership and Achievement Award by the International Society for CNS Drug Development, and he received the Bengt Winblad Lifetime Achievement Award from the national Alzheimer's Association. In 2019, the International Psychogeriatric Association awarded him with the Distinguished Service Award and he received the Alzheimer's Drug Discovery Foundation's Melvin R. Goodes Prize that honors an innovative researcher who has made a significant and lasting impact in the field. He was featured in the *Gentleman's Quarterly* (June 2009) as a "Rock Star of Science™". Dr. Cummings' interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. He completed a neurology residency and a fellowship in Behavioral Neurology at Boston University, Boston, Massachusetts. US training was followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London, England.

Dr. Cummings was formerly Augustas Rose Professor of Neurology and Professor of Psychiatry at UCLA, Director of the Mary S. Easton Center for Alzheimer's Disease Research at UCLA, and Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association. Dr. Cummings has authored or edited 43 books and published more than 800 peer-reviewed papers.

Ana M. Franceschi, MD
Northwell Health
New York, New York

Dr. Franceschi is highly motivated and dedicated to making significant contributions to advancing neuroradiology research and practice. Specifically, she has developed a special focus on neurological molecular imaging, with an emphasis on the advancement of brain PET/MRI and hybrid imaging techniques in dementia and neurodegenerative diseases. Early in her career, she collaborated with leading scientists in the molecular imaging field: in particular, Dr. Paul Vaska at the Brookhaven National Laboratory and Biomedical Engineering at Stony Brook University to study the utility of [18F]-FDG PET/MRI in assessing neurometabolic disruption following concussion injury in college student athletes.

Dr. Franceschi is co-investigator on the study "A Life Course Approach to Integrating Trauma and Cognitive Aging: A Cohort of 9/11 Responders" under the leadership of Dr. Sean Clouston at the Stony Brook School of Public Health, as part of the World Trade Center (WTC) responders aging program (NIH R01 AG049953; Clouston, PI). This research focuses on PTSD and WTC exposures as risk factors for cognitive dysfunction and decline alongside changes in ß-amyloid, tau deposition and

neurodegeneration in a prospective cohort of WTC responders. In 2019, she was honorary lecturer at the American Society of Neuroradiology International Symposium in Kiev, Ukraine, and outlined her custom PET/MRI post-processing workflow and hybrid imaging approach to neurodegenerative disorders. In addition to contributing to multiple scientific publications on this topic, Dr. Franceschi is lead editor of the textbook *Hybrid PET/MR Neuroimaging: A Comprehensive Approach* (Springer Nature, Geneva, Switzerland, 2021).

Douglas Galasko, MD
University of California San Diego
La Jolla, California

Dr. Douglas Galasko completed medical training in South Africa, a neurology residency at Johns Hopkins Medical School, and fellowship training in dementia/geriatric neurology at University of California San Diego (UCSD). He is a Professor in the Department of Neurosciences at UCSD and a Staff Physician at the VA Medical Center and has leadership roles in the NIA-funded Alzheimer's Disease Research Center and the Alzheimer's Disease Cooperative Study. His research interests include risk factors, diagnostic criteria and biomarkers for neurodegenerative disorders, as well as using biomarkers to aid in novel therapeutic development. He has authored more than 350 journal articles. He has participated in developing diagnostic criteria for AD, DLB and FTD, as well as guidelines for appropriate use of CSF biomarkers for AD. He has received research funding from NIH, the VA, the Michael J. Fox Foundation, and other foundations and organizations. He serves as advisor to the Michael J. Fox Foundation and the Lewy Body Dementia Association, as grant reviewer for NIH and a number of foundations and organizations, and as Editor of *Alzheimer's Research & Therapy*.

James Galvin, MD, MPH
University of Miami
Miami, Florida

Dr. Galvin is Professor of Neurology and Psychiatry & Behavioral Sciences at the University of Miami Miller School of Medicine. He is Founding Director of the Comprehensive Program for Brain Health, Director and Principal Investigator of the Lewy Body Dementia Research Center of Excellence, and Chief of Cognitive Neurology for Palm Beach and Broward Counties, leading brain health and neurodegenerative disease research and clinical programs. Dr. Galvin has authored more than 280 scientific publications, 25 book chapters, and 3 textbooks on healthy brain aging, cognitive health, memory loss, Alzheimer's disease, Lewy Body dementia, and related disorders. Dr. Galvin's research has been funded by the National Institutes of Health, Alzheimer's Association, Michael J Fox Foundation, Missouri, New York and Florida Departments of Health, and numerous private and family foundations.

cascADe: Courses On-demand Expert AD Educators

Regina V. Gibson, PhD, RN, MALS
University of Arkansas for Medical Sciences
Reynolds Institute on Aging
Little Rock, Arkansas

Regina V. Gibson, PhD, RN, MALS, gerontologist, is a certified health education specialist, certified clinical research professional, and a certified Alzheimer's Disease Dementia Care Trainer. She is currently an assistant professor/senior nurse educator in the Department of Geriatrics at the Donald W. Reynolds Institute on Aging at the University of Arkansas for Medical Sciences (UAMS) in Little Rock, Arkansas. Dr. Gibson has an extensive background in both basic science research and community-based participatory research involving cancer prevention.

Dr. Gibson served initially as replication coordinator for national dissemination of the Witness Project®, a breast and cervical cancer early detection program reaching out to African American women in community settings in Arkansas, and later as interim project director, having helped to implement the program in 23 states. She also previously served as director of cancer control for the Arkansas Special Populations Access Network, a cooperative agreement with the National Cancer Institute's Center to Reduce Health Disparities.

Over the past 4 years, Dr. Gibson has participated as a sub-investigator on a 5-week nutritional research study for African American women aged 60 years and older regarding optimizing nutrition for better health, and a protocol examining cardio-metabolic risk factors in older African American women that contribute to dementia as well as research on the cognitive health of African Americans as it relates to gut microbiomes.

Currently, as project director of a SAMHSA (Substance Abuse and Mental Health Services Administration) sponsored program on opioid prevention through the Division of Aging and Adult Behavioral Services, Dr. Gibson coordinated classes for older adults on opioid pain medications, non-opioid pain medications, and integrative therapies to assist in the management of chronic pain. More recently, UAMS initiated a 9-month Quality Improvement for Advanced Learners Program to work effectively on interprofessional quality improvement project teams while using quality improvement science methodology. Dr. Gibson served in the role as principal investigator on this team, to examine disparity in appropriate dementia screening of older African American adults vs that of older white adults. This dementia quality improvement project received a first-place award.

cascADe: Courses On-demand Expert AD Educators

Lawrence Honig, MD, PhD
Columbia University Irving Medical Center
New York, New York

Dr. Lawrence Honig is a Professor of Neurology at Columbia University Irving Medical Center in New York City. He is a neuroscientist and board certified clinical neurologist, with UCNS subspecialty certifications in Behavioral Neurology and Neuropsychiatry, and Geriatric Neurology. His clinical specialization focuses on aging and degenerative brain conditions, including Alzheimer's, Lewy Body, Frontotemporal, Progressive Supranuclear Palsy, and Creutzfeldt-Jakob diseases, and the immune-mediated encephalitides. His activities include clinical drug trial research, observational disease research, clinical neurological care, and translational investigations on molecular biomarkers of aging and dementia. He holds appointments in the Department of Neurology, the Gertrude H. Sergievsky Center, and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, at Columbia University, where he is Director of the New York State Center of Excellence for Alzheimer's Disease, a leader in the Alzheimer's Disease Research Center, and a Director of the Lewy Body Disease Association Research Center of Excellence. He received his undergraduate A.B. degree from Cornell University College of Arts and Sciences, his doctoral degree in Molecular Biology at the University of California at Berkeley, and his medical doctoral degree at the University of Miami (Florida). He trained in Internal Medicine and Neurology at Stanford University Medical Center (California), and held faculty appointments at Stanford University School of Medicine and the University of Texas Southwestern Medical Center at Dallas, prior to his move to Columbia University in New York City in the year 2000. He is a Fellow of the American Academy of Neurology, and a Member of the American Neurological Association, Movement Disorder Society, and Society for Neuroscience.

William T. Hu, MD, PhD
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Dr. Hu is a board certified neurologist with special certification in behavioral neurology and neuropsychiatry. He completed his medical and graduate school training at Mayo Medical School in Rochester, Minnesota, his adult neurology residency at the Mayo Clinic, and his American Academy of Neurology-sponsored cognitive neurology fellowship at the University of Pennsylvania, Philadelphia, Pennsylvania. He then joined the faculty at Emory University School of Medicine in 2010. He introduced and popularized modern biomarker-based diagnosis of mild cognitive impairment (MCI) and dementia to the Southeastern region, and was recruited to Rutgers in 2020 to head the Division of Cognitive Neurology.

Dr. Hu is also a physician-scientist who has made significant contributions to the field of dementia research. While still a neurology resident, he was the first to identify the brain region in Alzheimer's disease where a pathology more commonly seen in

frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), TDP-43, first appeared. The staging scheme he proposed remains in use across neuropathologic laboratories. After beginning his own research laboratory in 2010, he was the first to develop a reliable diagnostic test for FTD due to TDP-43, which has been replicated by 4 other groups; to show that Black/African Americans have different cerebrospinal fluid profiles of Alzheimer's disease and inflammation than White Americans, a finding which has significant implication in the diagnosis and treatment of Alzheimer's disease in Black/African Americans; and to identify important methods to better understand the intersection between brain dysfunction and inflammation across multiple diseases.

Michelle Mielke, PhD
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Dr. Mielke received a bachelor of science degree in neuroscience at the University of Pittsburgh in Pittsburgh, Pennsylvania, and a doctorate in psychiatric epidemiology from the Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland. She was previously a professor of epidemiology and neurology at the Mayo Clinic, Rochester, Minnesota, and the associate chair of Faculty Development and Academic Affairs in its Department of Quantitative Health Sciences. She recently joined Wake Forest University School of Medicine as chair of the Department of Epidemiology and Prevention and professor of epidemiology, neurology, and gerontology and geriatric medicine.

Dr. Mielke works as a translational epidemiologist to further understanding of the etiology and epidemiology of neurodegenerative diseases. One focus of her research is the identification of fluid biomarkers for the diagnosis, prediction, and progression of Alzheimer's disease and other neurodegenerative diseases. Her work, in both cerebrospinal fluid and blood, has emphasized the utility of lipids, total tau, phosphorylated tau, neurofilament light, and inflammatory markers in the general population. She is the past chair of the Biofluid-Based Biomarker Professional Interest Area under the Alzheimer's Association and a member of the Global Biomarkers Standardization Consortium (GBSC) and Standardization of Alzheimer's Blood Biomarkers (SABB).

Another focus of Dr. Mielke's research is on understanding sex and gender differences in the development and progression of Alzheimer's disease and of other aging-related conditions. She directs the Mayo Clinic Specialized Center of Research Excellence (SCORE) on Sex Differences. Dr. Mielke is co-chair of the Sex and Gender Diversity Group for the Alzheimer's Association Professional Interest Area. She received the John R. Raymond Mentor Award from the Women Scholars Initiative.

Dr. Mielke is an associate editor of *Alzheimer's & Dementia* and *Alzheimer's Research & Therapy*, and serves on multiple editorial boards. She serves on the Peripheral and Central Nervous System Drugs Advisory Committee (FDA) and Congressionally

Directed Medical Research Program (CDMRP) Peer Reviewed Alzheimer's Research Program (PRARP). She is the PI of several NIH- and Foundation-funded clinical- and epidemiological-based grants and has published more than 360 manuscripts.

Augusto Miravalle, MD
University of Colorado
Anschutz Medical Center
Aurora, Colorado

Augusto Miravalle, MD, is an associate professor of clinical neurology at the University of Colorado, Aurora, Colorado. He provides care to patients at Advanced Neurology of Colorado in Fort Collins. He is a board certified neurologist who sub-specializes in multiple sclerosis and dementias.

Dr. Miravalle received his medical degree from the University of La Plata, Buenos Aires, Argentina. He completed a neurology residency training at Loyola University, Chicago, Illinois, where he served as chief resident of education. He subsequently completed a neuroimmunology fellowship at Harvard University in Boston and a fellowship in medical education at the University of Rochester, New York. Dr. Miravalle is the recipient of the 2012 American Neurological Association Medical Education Fellowship Award, the 2015 American Academy of Neurology Research in Education Award, and the 2015 American Board of Psychiatry and Neurology Faculty Innovation in Education Award.

Dr. Miravalle has been involved in both clinical- and science-based research in the fields of multiple sclerosis and neuroimmunology. A member of many professional societies and advisory boards, he is frequently invited as speaker at national and international meetings. He has published numerous scientific articles and serves as a consultant to various scientific organizations.

Ziad Nasreddine, MD
MoCA Clinic
Québec
Canada

Dr. Nasreddine graduated from Medical School and Neurology from the University of Sherbrooke in Québec, Canada. He is certified by the Medical Board of California, and by the American Board of Psychiatry and Neurology. He completed a post-doctorate fellowship in Neurobehavior at UCLA, with Professor Jeffrey Cummings. He is the recipient of the Arista Sunlife Award of Excellence in the category: Young Quebec Professional. He is actively involved in clinical research in Alzheimer's disease and has created and developed the Montreal Cognitive Assessment test, MoCA, which is translated to 100 languages and dialects and is now used in 200 countries around the world. The test was recently selected by the White House to assess the cognitive functions of the President of the United States. He is affiliated with Charles LeMoyne

Hospital. He is Assistant Clinical Professor in Neurology at the University of Sherbrooke and is the founder and Director of the MoCA Clinic and Institute.

Alessandro Padovani, MD, PhD
Department of Clinical and Experimental Sciences
University of Brescia
Brescia
Italy

Alessandro Padovani, MD, PhD, is currently a Full Professor of Neurology at the University of Brescia and Director of the Institute of Neurology at the University Hospital “Spedali Civili” of Brescia. He received his medical degree from the University of Verona in 1986 and his Neurology Board Certificate at the University "La Sapienza" of Rome in 1990. During his residency, he held a Visiting Fellowship at Boston University from June 1988 through June 1989 under the supervision of Edith Kaplan and David Bachman. From 1991 to 1994, he was a PhD student in Neuropsychology at the University La Sapienza, Roma.

Since 2005, he has been a Full Professor of Neurology and Director of the Institute of Neurology at the University of Brescia. From March 2013 through October 2018, he was Dean of the School of Medicine and Elected Member of the Faculty of Medicine at the University of Brescia. From March 2012 through March 2014, he was President of the Italian Society for the Study of Dementia (SINDEM). He is the Vice-President of the Italian Association of Psychogeriatrics (AIP) and the Secretary of the Italian Society of Neurology (SIN).

His main scientific interests have turned to Cognitive Neuroscience, Neurodegenerative Diseases, including Parkinson’s Disease, Alzheimer’s disease, Fronto-Temporal Dementia, ALS, and Stroke. He is the author of more than 700 original scientific articles in major peer-reviewed scientific journals in the field of neurology, neurobiology, neuropsychology, and behavior. His H index is equal to 68 according to ISI Web of Science (July 2020). He has participated in national and international peer-reviewed research projects, as well as many clinical trials on Alzheimer’s disease. He is still involved in clinical research and has initiated collaborations with national and international public entities, including regulatory agencies, such as EMA and AIFA, and has served on several International Advisory Boards on Alzheimer’s Disease.

Monica W. Parker, MD
Goizueta Alzheimer’s Disease Research Center
Emory University
Atlanta, Georgia

Dr. Parker, a graduate of Fisk University, Nashville, Tennessee, and the University of Nebraska Medical Center, Omaha, Nebraska, joined the Emory University School of

Medicine (Atlanta, Georgia) faculty in 1995. She has transitioned roles from that of a geriatric, primary care provider to that of clinical research investigator. As such, she now leads the Minority Engagement Core (MEC), one of 8 cores of the Emory Goizueta Alzheimer's Disease Research Center.

Dr. Parker is a funded investigator on several National Institutes of Health-funded projects. She has co-authored several articles for peer-reviewed journals. She is a recipient of several honors, most recently that of a Yellow Rose Award by the Georgia Legislature Women's Caucus 2021.

Castle Connolly Associates named her one of Atlanta's Top Doctors in Family/Geriatric Medicine 2009-2013, as published in *Atlanta* magazine.

Derk Purcell, MD
California Pacific Medical Center
UC San Francisco
San Francisco, California

Dr. Derk Purcell is a neuroradiologist consultant with BioClinica in Newark, California, a neuroradiologist at the California Pacific Medical Center in San Francisco, and an Assistant Professor of Neuroradiology at the University of California, San Francisco (UCSF). Dr. Purcell earned his medical degree from UCSF and served an internship at St. Mary's Medical Center in San Francisco. He then completed a residency in diagnostic radiology and held a fellowship in neuroradiology, both at UCSF.

Dr. Purcell is board certified in diagnostic radiology and neuroradiology and serves as a manuscript reviewer for several journals, including *The Laryngoscope*, *American Journal of Neurology*, and *Neurosurgery*. He has authored or coauthored several book chapters and articles in peer-reviewed radiological journals and is a member of the American Neurological Society, the Radiological Society of North America, and the American College of Radiology.

Leslie Shaw, PhD
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Dr. Leslie Shaw, Professor, directs the Biomarker Research Laboratory at the Perelman School of Medicine, University of Pennsylvania, in the Department of Pathology and Laboratory Medicine. He is co-PI and co-director of the ADNI Biomarker Core laboratory and co-leads the Biomarker Core of the UPenn ADCC. He has published more than 280 scientific papers and reviews in the peer-reviewed literature. Among the major interests of Dr. Shaw are assessment and validation of pre-analytical steps involved in analyses of biofluids and the development and validation of methods for

quantification of CSF AD biomarkers, including Aβ42 and related Aβ peptides, t-tau and p-tau181, and new promising biomarkers in CSF and plasma for early disease detection. Dr. Shaw is especially interested in studies on the predictive performance of AD biomarkers for AD disease progression and relationships to imaging biomarkers in AD and AD-related disorders.

Sietske Sikkes, PhD
VUmc Alzheimer Center
Amsterdam
Netherlands

Sietske Sikkes, PhD, is an associate professor at the Department of Clinical, Neuro and Developmental Psychology of the VU University and the Alzheimer Center Amsterdam of the Amsterdam University Medical Center. With a background in clinical neuropsychology and epidemiology, her research focuses on the psychometrics of everyday functioning and cognition, and the development of new measurement techniques for the detection of clinically meaningful changes in the early stages of Alzheimer's disease. Dr. Sikkes is the PI and developer of the Amsterdam IADL Questionnaire (A-IADL-Q) and PI of projects such as 'Capturing Changes in Cognition'. Other research themes include diversity in measurement and nonpharmacological interventions, with a focus on prevention. Dr. Sikkes currently serves as chair of the ISTAART Professional Interest Area of 'subjective cognitive decline' and 'nonpharmacological interventions', and she is a member of the ISTAART Advisory Council.

Robert Stern, PhD
Boston University Alzheimer's Disease Research Center
Boston University School of Medicine
Boston, Massachusetts

Dr. Robert Stern is Professor of Neurology, Neurosurgery, and Anatomy & Neurobiology at Boston University (BU) School of Medicine. Dr. Stern has been a clinician, researcher, and educator in the area of Alzheimer's disease and related disorders for more than 30 years. From 2010 to 2019 he was Clinical Core Director of the NIH-funded BU Alzheimer's Disease Research Center (BU ADRC) and is currently Senior Scientist for the BU ADRC. He oversees several clinical trials for the treatment and prevention of Alzheimer's and has conducted research on innovative new tests to detect and diagnose the disease. Dr. Stern is an internationally recognized expert on chronic traumatic encephalopathy (CTE) and the long-term effects of repetitive head impacts in athletes. He is Co-Founder and Director of Clinical Research for the BU CTE Center, and he is the lead investigator of a $17 million, 7-year NIH grant for a multicenter study to develop methods of diagnosing CTE during life as well as examining potential risk factors of the disease. Dr. Stern has more than 250 publications, is a member of several medical journal editorial boards, and is the co-editor of two textbooks: *Sports Neurology*

(Dr. Brian Hainline, co-editor), part of the *Handbook of Clinical Neurology* series, and the *Oxford Handbook of Adult Cognitive Disorders* (Dr. Michael Alosco, co-editor). He is a clinical neuropsychologist and has developed several widely used neuropsychological tests, including the *Neuropsychological Assessment Battery* (NAB). He is a Fellow of the American Neuropsychiatric Association and the National Academy of Neuropsychology.

Dylan Wint, MD
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada

Dylan Wint, MD, serves as Interim Center Director at Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, where he also leads the Outreach Recruitment and Education Core of the Alzheimer Disease Research Center and holds a chair in Brain Health Education and endowed chairs in Brain Health and in Neuroscience Education. He is a clinical associate professor at Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio, and an adjunct assistant professor at Touro University Nevada in Henderson, Nevada. Dr. Wint earned his bachelor's degree in Biological Sciences from Stanford University and medical degree from the University of Miami, Florida, then completed simultaneous neurology and psychiatry residencies and fellowships in deep brain stimulation and multimodal neuroimaging. He is board certified in neurology, psychiatry, and behavioral neurology and neuropsychiatry.

Dr. Wint has authored a number of articles and book chapters in neuropsychiatry and has earned numerous clinical and academic awards. His focus is on optimizing the understanding, diagnosis and treatment of behavioral changes associated with neurodegenerative disorders, particularly Alzheimer's disease and other dementias.